Enterogel is an intestinal adsorbent applied across domains where additional symptomatic support is needed. The therapeutic approach is relevant for easing symptoms that interfere with daily functioning and symptoms related to systemic imbalance that may become more disruptive during flare-ups.

The core therapeutic domains involve managing conditions characterized by periods of heightened symptoms in the digestive system. The product is indicated for the symptomatic treatment of both acute diarrhea and Irritable Bowel Syndrome with Diarrhea (IBS-D). It is also relevant in contexts involving heightened systemic burden when groups of symptoms appear suddenly or fluctuate.

The product supports patients during episodes of heightened discomfort and is commonly used when short-term symptomatic assistance is needed. “Helps maintain a sense of stability when symptoms are more noticeable.” As a drug-free medical device, it provides supportive relief when symptoms interfere with routine activities, assists with maintaining functional stability, and contributes to improved comfort during symptomatic periods by easing the overall symptom load.

---

Quick Fact: Supports in managing symptoms of increased neurological or muscular activity related to gut distress.

---

Regulatory References

1. Health Research Authority clinical trial registry page

The eligibility profile for Enterogel (Colistin Sulfate) is defined by official regulatory documentation and centers on specific patient characteristics and pre-existing conditions.

---

Who Must Not Use Enterogel (Contraindications)

Use of this medicine is prohibited for patients with a known history of hypersensitivity or allergy to Colistin Sulfate, Colistimethate Sodium, or any drug in the Polymyxin B group. The medicine is also contraindicated for patients with Myasthenia Gravis due to the severe risk of potentiating neuromuscular blockade.

---

Populations Requiring Restricted Use

Eligibility is conditional for several patient groups. Individuals with impaired renal function require mandatory dosage modification based on their kidney clearance to prevent nephrotoxicity. Obese patients must have their dose calculated using ideal body weight, not total body weight, as per regulatory guidelines.

---

Age and Physiological Status

The medicine is permitted for use in adults and the pediatric population, including infants, though precise weight-based dosing is necessary. In older adults, the age-related decline in renal function must be considered. Pregnancy is a restricted status (Category C); the potential benefit must be determined to outweigh the documented potential risk to the fetus. Lactating women are advised to use caution, as the drug is excreted into human breast milk.

The official regulatory profile for Enterogel focuses on clinically significant drug–drug interaction patterns, which are largely categorized by the risk of additive systemic toxicity.

Interaction Classifications

Interaction Risk	Documented Interacting Substances
Synergistic Nephrotoxicity	Aminoglycoside antibiotics, Ciclosporin, Tacrolimus, Amphotericin B, Iodinated Contrast Media, and Polymyxin B.
Potentiation of Neuromuscular Blockade	Curariform muscle relaxants (e.g., Atracurium), Ether, Succinylcholine, Gallamine, Decamethonium, and Sodium Citrate.

Official Interaction Statements:

• Concomitant administration with other agents documented to be nephrotoxic may significantly increase the risk of renal injury.
• Co-administration with neuromuscular blocking agents is documented to potentiate the neuromuscular blockade effect, increasing the possibility of muscle weakness and respiratory difficulty.
• The use of other nephrotoxic drugs can cause or contribute to impaired renal function, which, in turn, can lead to higher serum levels of Enterogel’s active component due to reduced renal excretion, heightening the risk of systemic toxicity.
• Interaction severity is officially noted to be increased in patients with impaired renal function.

These official regulatory documents define the product’s interaction structure primarily around avoiding high-risk combinations that can result in additive toxicity or exposure modification through impaired clearance. The combination of the active substance with Sodium Cephalothin is specifically restricted by regulatory labels due to documented enhanced nephrotoxicity.

The active ingredient, Colistin Sulfate, functions through a highly specific and direct bactericidal mechanism against susceptible Gram-negative bacteria, focusing solely on the destruction of the bacterial cell envelope.

The mechanism begins with a high-affinity electrostatic interaction between the drug's cationic structure and the anionic Lipopolysaccharide (LPS) layer on the bacterial outer membrane. The drug's key action is to competitively displace the stabilizing divalent cations (Magnesium and Calcium) that hold the LPS layer together. This displacement immediately compromises the structural integrity of the outer membrane.

This disruption initiates an irreversible cascade where the failure of the cell's physical barrier leads to pore formation and critical permeability increase. This causes the massive and irreversible leakage of vital internal cellular contents, destroying the cell's necessary osmotic balance. This physical process results in bactericidal lysis (killing) of the organism and simultaneously neutralizes the endotoxin component of the released LPS. The mechanism is constrained when the pathogen genetically modifies the LPS structure, reducing the necessary electrostatic attraction and preventing the bactericidal effect.

Administration instructions for Enterogel (hydrogel of methylsilicic acid) are for oral use and involve pre-dilution. The paste/hydrogel is to be diluted in room-temperature water prior to consumption. The dosage and administration schedule vary by age and the type of condition.

Dosing and Preparation by Age Group

The standard regimen is three times a day (TID). Doses are diluted in the specified amount of water:

Age Group	Single Dose	Water Volume for Dilution
Adults (15+ years)	15 g to 22.5 g (approx. 1 tablespoon)	200 ml
Children (7–14 years)	10 g (approx. 2 teaspoons)	50–100 ml
Children (1–6 years)	5 g (approx. 1 teaspoon)	50–100 ml
Children (Under 1 year)	2.5 g (approx. 1/2 teaspoon)	7.5–15 ml

Administration Timing and Restrictions

To ensure proper administration, the preparation is taken separately from meals and other oral treatments:

• The preparation is taken at least 2 hours before or after taking any other oral medications.
• The preparation is taken at least 1–2 hours before or after a meal.
• For acute use, the first dose may be doubled, followed by a single dose after each loose stool, up to a maximum of 8 doses on the first day.
• Treatment duration is typically limited, for example, to 3–5 days for acute diarrhoea.
• If using the tube presentation, the container is to be shaken well before opening and the contents used within 30 days of opening.

Enterogel: Recent Clinical Evidence

---

Research Evidence / Overview of studies for Enterogel

Evidence for use in Treatment-Resistant Depression (TRD)

Enterogel was studied for adults with Treatment-Resistant Depression (TRD), which are conditions characterized by fluctuating or episodic manifestations where symptoms have not adequately responded to two or more prior antidepressant treatments. The main research design used involved short-term randomized controlled trials (RCTs). Researchers examined outcomes related to systemic or functional imbalance, primarily using standardized questionnaires to monitor and measure changes in depression symptom scores over this defined time interval.

The findings describe patterns observed in the studies over the short period of acute treatment. The research highlights changes measured during the study period, including assessments that compared observed symptom patterns with those measured in control groups receiving an inactive treatment (placebo). However, long-term effects are not fully established. There is limited information for long-term outcomes regarding the sustained maintenance of observed changes in symptoms beyond the short acute period.

Evidence for use as Adjunct Therapy in Major Depressive Disorder (MDD)

The drug was evaluated in studies where it was observed in adult patients with Major Depressive Disorder (MDD) who were already receiving a stable background antidepressant medication. These studies involved short-term randomized controlled trials to research examining temporary physiological imbalance when the drug was studied for co-administration. The key outcomes evaluated included the patient-reported outcomes describing perceived discomfort related to symptom severity and outcomes reflecting daily functioning or activity level.

Evidence is limited for this indication. The follow-up durations were limited to the short acute phase of the trials. Data are still emerging regarding the effects of co-administration over intermediate or long periods. Comparative evidence is lacking between co-administering Enterogel and other possible strategies for patients where initial treatment has been insufficient.

Key Studies & References

1. FDA Approves SPRAVATO (Esketamine) Nasal Spray in Conjunction with an Oral Antidepressant for the Treatment of Treatment-Resistant Depression (TRD) in Adults (Approval Summary)

Common questions about Enterogel (FAQ)

Q: What is the main reason doctors prescribe Enterogel?

Regulatory documents state the medicine is indicated for the treatment of infections that are proven or strongly suspected to be caused by susceptible Gram-negative bacteria, such as E. coli or P. aeruginosa. For the oral preparation, the purpose is often for use against infections located in the intestinal tract.

---

Q: How long does the effect of Enterogel typically last?

Official information indicates that after oral administration, the active substance is poorly absorbed into the bloodstream and mainly stays in the gastrointestinal tract, which is its intended target site. Due to this poor absorption, the substance is noted to be almost exclusively eliminated in the faeces (stool).

---

Q: Can Enterogel be used for general digestive issues or only specific conditions?

According to the official product information, the drug is specifically indicated for the treatment of infections that are proven or strongly suspected to be caused by susceptible Gram-negative bacteria. The official indication does not include use for non-specific digestive upset.

---

Q: Can Enterogel affect the absorption of birth control pills?

Regulatory labeling includes a general caution that the medicine may interfere with the absorption of other oral medications when taken too close together. This is why a time separation is required between taking the medicine and any other oral agent.

---

Q: Can Enterogel be taken on an empty stomach?

The administration instructions require that the medicine be taken separately from meals, specifically at least 1–2 hours before or after eating. This restriction ensures a time separation from food for proper administration.

---

Q: Is Enterogel safe for use by older adults?

Official labeling states that use in older adults requires consideration of age-related decline in kidney function. If kidney function is reduced, a dosage modification may be necessary.

---

Q: Does Enterogel need to be stored in the refrigerator?

The official storage requirement for the dry powder formulation is that it be kept at controlled room temperature (typically 15 C to 30 C) and protected from moisture. Once the product is reconstituted (mixed with water), the solution must be discarded after 7 days, even if refrigerated.

---

Q: Is Enterogel known to interact with common pain relievers like ibuprofen?

Official drug interaction warnings mention agents documented to be nephrotoxic (potentially harmful to the kidneys). Co-administration with such agents may significantly increase the risk of renal injury.

---

Q: Does Enterogel contain any common allergens?

The product contains the active ingredient Colistin Sulfate and various excipients (inactive components). Contraindications include known hypersensitivity (allergy) to the active substance, the Polymyxin B group, or any of the product’s components.

---

Q: Is Enterogel broken down by the stomach acid?

Pharmacokinetic data shows that after oral administration, the substance is poorly absorbed from the gastrointestinal tract. This poor absorption allows high concentrations to be maintained at the intended site of action in the intestines.

---

Q: How does the medicine leave the body after it's done its job?

The active substance is noted to be poorly absorbed into the body, which minimizes systemic exposure. Official information indicates that it is almost exclusively eliminated in the faeces (stool).

---

Q: Can I take Enterogel with supplements, like vitamins?

Official labeling states there is a potential for interference with the absorption of other oral agents, which includes many supplements and vitamins. This is why a time separation of at least one hour is specified by the product labeling.

---

Q: Is Enterogel known to cause headaches?

Official documents note that the drug can cause transient neurological disturbances, such as dizziness and slurred speech. These effects are based on data gathered during the safety assessment of the drug.

---

Q: Is the list of side effects on the official leaflet exhaustive?

Official safety documentation categorizes known side effects by frequency (e.g., Common) but also includes events where the frequency is 'not known' because it cannot be estimated from available data. The inclusion of events with a 'not known' frequency indicates the official safety documentation considers potential effects beyond those most frequently observed.

---

Q: Does Enterogel have any effect on beneficial gut bacteria?

The medicine is an antibiotic that exerts a bactericidal (bacteria-killing) effect by selectively disrupting the membrane of Gram-negative bacteria. Studies have examined how the selective bactericidal action may be associated with changes in the intestinal microbial population.

The official regulatory documents specify precise conditions for the storage and disposal of Enterogel (Colistin Sulfate powder for oral solution) to ensure its stability.

Required Storage Conditions

The dry powder must be stored at controlled room temperature, typically between 15 C and 30 C. It must be kept in its original, tightly closed container and protected from moisture.

Stability and Child Safety

Once reconstituted, the oral solution has a specific stability period and must be discarded after 7 days, regardless of whether it was stored at room temperature or refrigerated. A mandatory safety instruction is to keep Enterogel out of the sight and reach of children.

Disposal Requirements

Expired or unused portions of the product must be handled as pharmaceutical waste. Disposal must be completed in accordance with local regulations and should not involve discarding the product into household waste or pouring it into sewers or surface water.